SI20107A - Metode za preprečevanje raka na dojki - Google Patents

Metode za preprečevanje raka na dojki Download PDF

Info

Publication number
SI20107A
SI20107A SI9720070A SI9720070A SI20107A SI 20107 A SI20107 A SI 20107A SI 9720070 A SI9720070 A SI 9720070A SI 9720070 A SI9720070 A SI 9720070A SI 20107 A SI20107 A SI 20107A
Authority
SI
Slovenia
Prior art keywords
day
breast cancer
compound
effective dose
preparation
Prior art date
Application number
SI9720070A
Other languages
English (en)
Slovenian (sl)
Inventor
J. Fredric Cohen
S. Robert Eckert
E. Joan Glusman
K. Ronald Knickerbocker
T. Nikolaus Nickelsen
J. Teri Scott
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27268608&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI20107(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9624800.0A external-priority patent/GB9624800D0/en
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of SI20107A publication Critical patent/SI20107A/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SI9720070A 1996-10-30 1997-10-29 Metode za preprečevanje raka na dojki SI20107A (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2985096P 1996-10-30 1996-10-30
GBGB9624800.0A GB9624800D0 (en) 1996-11-29 1996-11-29 Methods of preventing breast cancer
US4026097P 1997-03-10 1997-03-10
PCT/US1997/019779 WO1998018449A1 (en) 1996-10-30 1997-10-29 Methods of preventing breast cancer

Publications (1)

Publication Number Publication Date
SI20107A true SI20107A (sl) 2000-06-30

Family

ID=27268608

Family Applications (3)

Application Number Title Priority Date Filing Date
SI9720070A SI20107A (sl) 1996-10-30 1997-10-29 Metode za preprečevanje raka na dojki
SI9730529T SI0839532T1 (en) 1996-10-30 1997-10-29 Improvements in or relating to the prophylaxis of breast cancer by the administration of raloxifene
SI9730752T SI1369115T1 (sl) 1996-10-30 1997-10-29 Postopek za preprecevanje raka na dojki z administracijo raloksifena

Family Applications After (2)

Application Number Title Priority Date Filing Date
SI9730529T SI0839532T1 (en) 1996-10-30 1997-10-29 Improvements in or relating to the prophylaxis of breast cancer by the administration of raloxifene
SI9730752T SI1369115T1 (sl) 1996-10-30 1997-10-29 Postopek za preprecevanje raka na dojki z administracijo raloksifena

Country Status (44)

Country Link
US (2) US6303634B1 (xx)
EP (3) EP0839532B1 (xx)
JP (2) JPH10147530A (xx)
CN (2) CN1182591A (xx)
AP (1) AP971A (xx)
AR (2) AR013864A1 (xx)
AT (2) ATE338551T1 (xx)
AU (3) AU5005197A (xx)
BE (2) BE1011381A5 (xx)
BG (1) BG63841B1 (xx)
BR (1) BR9712703A (xx)
CA (2) CA2219377A1 (xx)
CH (2) CH693820A5 (xx)
CZ (2) CZ341297A3 (xx)
DE (2) DE69721692T2 (xx)
DK (2) DK0839532T3 (xx)
EA (2) EA006083B1 (xx)
EE (1) EE03663B1 (xx)
ES (4) ES2135343A1 (xx)
FR (2) FR2756490B1 (xx)
GB (3) GB2318733A (xx)
GE (1) GEP20032910B (xx)
GR (2) GR1003189B (xx)
HK (1) HK1010495A1 (xx)
HU (2) HUP9701777A3 (xx)
IE (2) IE970772A1 (xx)
IL (2) IL122026A0 (xx)
IS (1) IS5035A (xx)
IT (2) IT1298470B1 (xx)
LU (2) LU90157B1 (xx)
LV (1) LV12353B (xx)
MY (1) MY121623A (xx)
NL (2) NL1007387C2 (xx)
NO (2) NO974973D0 (xx)
NZ (1) NZ329042A (xx)
PT (2) PT839532E (xx)
RO (1) RO120813B1 (xx)
SG (2) SG83672A1 (xx)
SI (3) SI20107A (xx)
SK (1) SK287047B6 (xx)
TR (1) TR199900951T2 (xx)
UA (1) UA46762C2 (xx)
WO (2) WO1998018325A1 (xx)
YU (1) YU42397A (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458811B1 (en) * 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
GB9624800D0 (en) * 1996-11-29 1997-01-15 Lilly Co Eli Methods of preventing breast cancer
FI109332B (fi) 1998-12-17 2002-07-15 Orion Yhtymae Oyj Toremifeenin liukoisia koostumuksia
FI982733A (fi) * 1998-12-17 2000-06-18 Orion Yhtymae Oyj Trifenyylietyleeniantiestrogeenien liukoisia koostumuksia
EP1395563B1 (en) 2001-05-22 2006-03-29 Eli Lilly And Company 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods
US6962928B2 (en) 2001-05-22 2005-11-08 Eli Lilly And Company Tetrahydroquinoline derivatives for the inhibition of osteoporosis, estrogen dependent breast cancer, endometriosis and uterine fibrosis
US20040225200A1 (en) * 2003-05-09 2004-11-11 Edmundson Catherine M. System and method of analyzing the health of a population
GR1005694B (el) * 2005-06-08 2007-10-22 Αλεξης Μιχαηλ Ιστοειδικα αντιοιστρογονα ειδικα για τον αλφα υποδοχεα των οιστρογονων
UA97813C2 (uk) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
MD36Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare
MD35Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare
MD23Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare
MD24Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare
WO2011099942A1 (en) 2010-02-09 2011-08-18 Silverstone Pharma New addition salts of raloxifene, process for the preparation thereof and use thereof in therapy
CN102973573B (zh) * 2012-11-28 2015-04-08 玉林师范学院 一种人乳腺癌细胞抑制剂及制备方法
CN103830197A (zh) * 2014-03-14 2014-06-04 崔书豪 一种盐酸雷洛昔芬分散片及其制备方法
CN116650484A (zh) * 2023-05-11 2023-08-29 南通大学 一种乳腺癌相关蛋白的抑制剂及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4656187A (en) * 1981-08-03 1987-04-07 Eli Lilly And Company Treatment of mammary cancer
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
IL111287A0 (en) * 1993-10-15 1994-12-29 Lilly Co Eli Methods for treating resistant neoplasms
US5478847A (en) * 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
IL112746A (en) * 1994-03-02 1999-12-31 Lilly Co Eli Orally administrable pharmaceutical formulation comprising raloxifene hydrochoride
US5604248A (en) * 1994-05-05 1997-02-18 Eli Lilly And Company Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs
US5521214A (en) * 1995-01-25 1996-05-28 Eli Lilly And Company Methods of inhibiting environmental estrogens
US5821254A (en) 1995-02-17 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Uses of 9-cis-retinoic acids and derivatives thereof alone or in combination with antineoplastic agents in the prevention or treatment of cancer
ES2341399T3 (es) * 1996-03-26 2010-06-18 Eli Lilly And Company Benziotofenos, formulaciones que contienen los mismos y procedimientos.

Also Published As

Publication number Publication date
GEP20032910B (en) 2003-03-25
GB2318733A (en) 1998-05-06
AP9901494A0 (en) 1999-03-31
CN1182590A (zh) 1998-05-27
WO1998018325A1 (en) 1998-05-07
SG83672A1 (en) 2001-10-16
GB2318734A (en) 1998-05-06
HUP9701777A3 (en) 1999-07-28
AU5005197A (en) 1998-05-22
NO974972L (no) 1998-05-04
PT839532E (pt) 2003-09-30
ES2135342B1 (es) 2000-05-16
DE69721692T2 (de) 2004-03-25
IL122026A0 (en) 1998-03-10
EE03663B1 (et) 2002-04-15
ITMI972433A1 (it) 1999-04-29
US20020019418A1 (en) 2002-02-14
ITMI972434A1 (it) 1999-04-29
EP1369115A1 (en) 2003-12-10
DE69736644T2 (de) 2007-10-25
NL1007386C2 (nl) 1998-05-14
ES2197312T3 (es) 2004-01-01
FR2755014B1 (fr) 1999-02-05
FR2756490A1 (fr) 1998-06-05
ES2135343A1 (es) 1999-10-16
EA002054B1 (ru) 2001-12-24
NZ329042A (en) 1999-08-30
CA2219070C (en) 2007-12-18
CZ300261B6 (cs) 2009-04-01
NO974972D0 (no) 1997-10-28
EP0839532B1 (en) 2003-05-07
US6303634B1 (en) 2001-10-16
EA200100716A1 (ru) 2002-06-27
SK287047B6 (sk) 2009-10-07
GB2318734B (en) 1999-12-01
AU4364797A (en) 1998-05-07
CH691847A5 (fr) 2001-11-15
AU5005697A (en) 1998-05-22
FR2755014A1 (fr) 1998-04-30
CZ341197A3 (cs) 1998-05-13
GR970100408A (el) 1998-06-30
TR199900951T2 (xx) 1999-07-21
GR1003189B (el) 1999-09-01
UA46762C2 (uk) 2002-06-17
CA2219377A1 (en) 1998-04-30
IE970773A1 (en) 2000-02-09
CA2219070A1 (en) 1998-04-30
NO974973D0 (no) 1997-10-28
LU90157B1 (fr) 1998-06-02
JPH10147530A (ja) 1998-06-02
ES2271476T3 (es) 2007-04-16
LU90158B1 (fr) 1998-06-02
MX9708340A (es) 1998-08-30
ATE338551T1 (de) 2006-09-15
CZ341297A3 (cs) 1998-05-13
HUP9701778A3 (en) 1999-06-28
EA199900431A1 (ru) 1999-10-28
IT1298470B1 (it) 2000-01-10
CN1182591A (zh) 1998-05-27
NL1007387C2 (nl) 1998-05-14
LV12353A (lv) 1999-10-20
LV12353B (en) 2000-02-20
IL122025A0 (en) 1998-03-10
AR013864A1 (es) 2001-01-31
GR970100409A (el) 1998-06-30
ES2135342A1 (es) 1999-10-16
EA006083B1 (ru) 2005-08-25
HUP9701777A2 (hu) 1999-06-28
GB9911557D0 (en) 1999-07-21
SI1369115T1 (sl) 2006-12-31
DE69721692D1 (de) 2003-06-12
EP0839533A1 (en) 1998-05-06
DK0839532T3 (da) 2003-08-25
DK1369115T3 (da) 2007-01-02
ATE239475T1 (de) 2003-05-15
WO1998018449A1 (en) 1998-05-07
BG63841B1 (bg) 2003-03-31
MY121623A (en) 2006-02-28
BE1011382A5 (fr) 1999-08-03
HUP9701778A2 (hu) 1999-01-28
MX9708341A (es) 1998-08-30
AU731388B2 (en) 2001-03-29
PT1369115E (pt) 2006-12-29
RO120813B1 (ro) 2006-08-30
GB9722796D0 (en) 1997-12-24
HK1010495A1 (en) 1999-06-25
IS5035A (is) 1999-04-27
IE970772A1 (en) 2000-02-09
EP0839532A1 (en) 1998-05-06
SI0839532T1 (en) 2003-10-31
AR010538A1 (es) 2000-06-28
SK55999A3 (en) 2000-06-12
EP1369115B1 (en) 2006-09-06
JPH10147529A (ja) 1998-06-02
EE9900162A (et) 1999-12-15
NO322468B1 (no) 2006-10-09
BG103369A (en) 2000-05-31
CH693820A5 (fr) 2004-02-27
BE1011381A5 (fr) 1999-08-03
FR2756490B1 (fr) 2003-06-20
BR9712703A (pt) 1999-10-26
AU4364897A (en) 1998-05-07
IL122025A (en) 2003-01-12
SG72765A1 (en) 2000-05-23
YU42397A (sh) 2000-10-30
AP971A (en) 2001-05-30
GB9722801D0 (en) 1997-12-24
DE69736644D1 (de) 2006-10-19
HU9701777D0 (en) 1997-12-29
HU9701778D0 (en) 1997-12-29

Similar Documents

Publication Publication Date Title
SI20107A (sl) Metode za preprečevanje raka na dojki
HUT71480A (en) Pharmaceutical compositions for inhibition of breast disorders containing 2-phenyl-3-aroyl-benzothiophene-derivatives and process for their preparation
RU2203060C2 (ru) Способ профилактики рака молочной железы
US20040167170A1 (en) Methods of preventing breast cancer
KR100522646B1 (ko) 유방암의예방방법
AU2004231254B8 (en) Methods of preventing breast cancer
NZ292017A (en) Use of raloxifene to treat endometrial cancer
IL152080A (en) Use of raloxifene or pharmaceutically acceptable salts or solvates thereof in the preparation of a medicament for preventing breast cancer
NZ294123A (en) Use of a 2-phenyl-3-phenylcarbonyl-benzothiophene derivative for inhibiting endometrial mitoses
MXPA97008341A (en) Procedures to prevent the cancer of m
KR19980033284A (ko) 개선된 유방암 예방법

Legal Events

Date Code Title Description
IF Valid on the event date
KO00 Lapse of patent

Effective date: 20080724